PF-07976016 + YP05002

PF-07976016 + YP05002 (also known as PF-07976016 + PF-08642534) is an investigational combination therapy developed for the treatment of obesity and chronic weight management. The combination pairs two oral small molecules: PF-07976016, a selective glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist developed by Pfizer, and YP05002 (PF-08642534), an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist discovered by YaoPharma (a subsidiary of Shanghai Fosun Pharmaceutical). Pfizer licensed YP05002 globally in December 2025 with plans to evaluate it in combination with PF-07976016 to achieve synergistic weight loss through dual-pathway targeting. However, in August 2026, Pfizer discontinued the clinical development of PF-07976016 following a review of Phase 2a data, effectively halting the development of this specific combination.